Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas

Investigative Radiology

Volumn 47, Issue 1, 2012, Pages 49-57

  Cyran, Clemens C ^a   Von Einem, Jobst C ^a   Paprottka, Philipp M ^a   Schwarz, Bettina ^a   Ingrisch, Michael ^a   Dietrich, Olaf ^a   Hinkel, Rabea ^a   Bruns, Christiane J ^a   Clevert, Dirk A ^a   Eschbach, Ralf ^a   Reiser, Maximilian F ^a   Wintersperger, Bernd J ^a,b   Nikolaou, Konstantin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

DCE CT; Imaging biomarkers; Immunohistochemical validation; Prostate carcinoma allografts; Sorafenib

Indexed keywords

IOPROMIDE; KI 67 ANTIGEN; PLACEBO; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; BLOOD VOLUME; CELL PROLIFERATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE MARKER; DRUG MONITORING; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; SURFACE PROPERTY; TREATMENT DURATION; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 84155163259     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182300fe4     Document Type: Article

References (53)

1. Antonelli A, Ferri C, Ferrari SM, et al. New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol. 2010;2010:921682. doi: 10.1155/ 2010/921682.
2. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8:15-27.
3. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010;16:3526-3532.
4. Hopper KD, Singapuri K, Finkel A. Body CT and oncologic imaging. Radiology. 2000;215:27-40.
5. Dugdale PE, Miles KA, Bunce I, et al. CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. J Comput Assist Tomogr. 1999;23:540-547.
6. Bellomi M, Petralia G, Sonzogni A, et al. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology. 2007;244:486-493.
7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
8. Tai JH, Tessier J, Ryan AJ, et al. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia. 2010;12:697-707.
9. Smith AD, Shah SN, Rini BI, et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am J Roentgenol. 2010;194:1470-1478. doi: 194/6/1470 -pii- 10.2214/AJR.09.3456.
10. Lazanyi KS, Abramyuk A, Wolf G, et al. Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy. Lung Cancer. 2010;70:280-285. doi: S0169-5002(10)00117-0 -pii- 10.1016/j.lungcan.2010.03.004.
11. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol. 2003;76(spec no 1):S36-S42.
12. Miles KA, Charnsangavej C, Lee FT, et al. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol. 2000;7:840-850.
13. Miles KA, Griffiths MR. Perfusion CT: a worthwhile enhancement? Br J Radiol. 2003;76:220-231.
14. Tateishi U, Kusumoto M, Nishihara H, et al. Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer. 2002;95:835-842.
15. Lind JS, Meijerink MR, Dingemans AM, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol. 2010;20:2890-2898.
16. Petralia G, Bonello L, Viotti S, et al. CT perfusion in oncology: how to do it. Cancer Imaging. 2010;10:8-19.
17. Hermans R, Meijerink M, Van den Bogaert W, et al. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:1351-1356.
18. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574.
19. Hutson TE, Figlin RA. Experimental therapy for advanced renal cell carcinoma. Expert Opin Investig Drugs. 2008;17:1693-1702.
20. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851-11858.
21. Froehner M, Hakenberg OW, Wirth MP. Molecular therapy in urologic oncology. Urol Int. 2007;79:1-7.
22. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323-2330.
23. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009;103:1636-1640.
24. Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616-624.
25. Delgado JS, Mustafi R, Yee J, et al. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci. 2008;53:3055-3064.
26. Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol. 2008;19: 746-751.
27. Sourbron S, Dujardin M, Makkat S, et al. Pixel-by-pixel deconvolution of bolus-tracking data: optimization and implementation. Phys Med Biol. 2007; 52:429-447.
28. Sourbron S, Ingrisch M, Siefert A, et al. Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med. 2009;62:205-217.
29. Sourbron SP, Michaely HJ, Reiser MF, et al. MRI-measurement of perfusion and glomerular filtration in the human kidney with a separable compartment model. Invest Radiol. 2008;43:40-48.
30. Preda A, Novikov V, Moglich M, et al. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol. 2005;15:2268-2275.
31. de Bazelaire C, Siauve N, Fournier L, et al. Comprehensive model for simultaneous MRI determination of perfusion and permeability using a blood-pool agent in rats rhabdomyosarcoma. Eur Radiol. 2005;15:2497-2505. doi: 10.1007/s00330-005-2873-z.
32. Sourbron SP, Buckley DL. On the scope and interpretation of the Tofts models for DCE-MRI. Magn Reson Med. 2011;66:735-745.
33. Guidelines for Collection of Blood from Experimental Animals. 2006. Available at: http://www.ahc.umn.edu/rar/blood.html.
34. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936-1948.
35. Meijerink MR, van Waesberghe JH, van Schaik C, et al. Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities. Ultrasound Med Biol. 2010;36:1626-1636. doi: S0301-5629(10)00306-6 -pii- 10.1016/j.ultrasmedbio.2010.06.015.
36. Fournier LS, Oudard S, Thiam R, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology. 2010;256:511-518. doi: radiol.10091362 -pii- 10.1148/radiol.10091362.
37. Goetti R, Leschka S, Desbiolles L, et al. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol. 2010;45:419-426.
38. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49(suppl 2):113S-128S.
39. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 256:348-364.
40. Pollard RE, Larson RF. Dynamic contrast-enhanced computed tomography for the quantification of tumor response to vasoactive agents in a rat tumor model: preliminary results. Contrast Media Mol Imaging. 2011;6:28-34.
41. Cyran CC, Fu Y, Raatschen HJ, et al. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging. 2008;27:581-589.
42. Raatschen HJ, Fu Y, Brasch RC, et al. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol. 2009;44:265-270.
43. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
44. Goh V, Halligan S, Daley F, et al. Colorectal tumor vascularity: quantitative assessment with multidetector CT-do tumor perfusion measurements reflect angiogenesis? Radiology. 2008;249:510-517.
45. Henderson E, Milosevic MF, Haider MA, et al. Functional CT imaging of prostate cancer. Phys Med Biol. 2003;48:3085-3100.
46. Kershaw LE, Buckley DL. Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med. 2006;56:986-992.
47. Jeukens CR, van den Berg CA, Donker R, et al. Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT. Phys Med Biol. 2006;51:4329-4343.
48. Kershaw LE, Hutchinson CE, Buckley DL. Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009;29:641-648.
49. Buckley DL, Roberts C, Parker GJ, et al. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging-initial experience. Radiology. 2004;233:709-715.
50. Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009;27:404-410.
51. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005;23:6771-6790.
52. Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer. 2006;119:2261-2271.
53. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-3140.